Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma

Rausch, Steffen; Hennenlotter, Jörg; Scharpf, Marcus; Teepe, Katharina; Kühs, Ursula; Aufderklamm, Stefan; Bier, Simone; Mischinger, Johannes; Gakis, Georgios; Stenzl, Arnulf; Schwentner, Christian; Todenhöfer, Tilman

doi:10.1007/s00432-015-2107-y

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTOV1 was firstly identified and reported to be overexpressed in prostate cancer [14]. Later, it was found that high levels of PTOV1 correlated with poor prognosis of prostate cancer [35], breast cancer [20], urothelial carcinoma [36] and so on. Using tissue microarrays, Sara et al unveiled high expression of PTOV1 in lung cancer [15].…”

Section: Discussionmentioning

confidence: 99%

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

Liu

Jiang

et al. 2019

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Prostate tumor over expressed gene 1 (PTOV1) has been reported as an oncogene in several human cancers. However, the clinical significance and biological role of PTOV1 remain elusive in non-small cell lung cancer (NSCLC). Methods The Cancer Genome Atlas (TCGA) data and NCBI/GEO data mining, western blotting analysis and immunohistochemistry were employed to characterize the expression of PTOV1 in NSCLC cell lines and tissues. The clinical significance of PTOV1 in NSCLC was studied by immunohistochemistry statistical analysis and Kaplan–Meier Plotter database mining. A series of in-vivo and in-vitro assays, including colony formation, CCK-8 assays, flow cytometry, wound healing, trans-well assay, tumor sphere formation, quantitative PCR, gene set enrichment analysis (GSEA), immunostaining and xenografts tumor model, were performed to demonstrate the effects of PTOV1 on chemosensitivity of NSCLC cells and the underlying mechanisms. Results PTOV1 is overexpressed in NSCLC cell lines and tissues. High PTOV1 level indicates a short survival time and poor response to chemotherapy of NSCLC patients. Depleting PTOV1 increased sensitivity to chemotherapy drugs cisplatin and docetaxel by increasing cell apoptosis, inhibiting cell migration and invasion. Our study verified that depleting PTOV1 attenuated cancer stem cell traits through impairing DKK1/β-catenin signaling to enhance chemosensitivity of NSCLC cells. Conclusion These results suggest that PTOV1 plays an important role in the development and progression of human NSCLC and PTOV1 may serve as a therapeutic target for NSCLC patients. Electronic supplementary material The online version of this article (10.1186/s13046-019-1349-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

Liu

Jiang

et al. 2019

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…In aggressive prostate tumors, PTOV1 stained intensely in the nucleus of local and distal (bones) metastatic cells [33]. In urothelial carcinoma (UC) nuclear staining was significantly more frequent compared to benign tissue and a reduced cytoplasmic expression significantly correlated with higher pathological stage and grade, suggesting a functional shift for PTOV1 from the cytoplasm to the nucleus in the progression of these tumors [42]. These observations are in line with previous reports showing that intense nuclear PTOV1 expression was able to distinguish in a significant manner high-grade urothelial carcinoma [40].…”

Section: Ptov1 Expression In Normal and Cancer Tissuesmentioning

confidence: 99%

The role of prostate tumor overexpressed 1 in cancer progression

et al. 2016

View full text Add to dashboard Cite

“…9 It also has been reported to regulate many types of tumors and is a poor prognosis factor for squamous cell carcinoma, invasive urothelial carcinoma, nasopharyngeal carcinoma, bladder carcinoma, early-stage human laryngeal squamous cell carcinoma, and breast cancer. [10][11][12][13][14][15] A previous study suggested that PTOV1 is a poor prognosis factor for epithelial ovarian cancer; 16 however, the role of PTOV1 in ovarian cancer progression has not been studied. The present study aimed to investigate the role of PTOV1 in ovarian cancer chemotherapy resistance.…”

Section: Introductionmentioning

confidence: 99%

PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer

Shen

Liao

Wan

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Chemotherapy resistance is a bottleneck for ovarian cancer treatment; therefore, revealing its regulatory mechanism is critical. In the present study, we found that prostate tumor overexpressed-1 (PTOV1) was upregulated significantly in ovarian cancer cells and tissues. Patients with high PTOV1 levels had a poor outcome. In addition, PTOV1 overexpression increased CDDP (cisplatin) resistance, while PTOV1 knockdown inhibited CDDP resistance, as determined using cell viability assays, apoptosis assays, and an animal model. Mechanistic analysis showed that PTOV1 increased nuclear factor kappa B (NF-κB) pathway activity, reflected by increased nuclear translocation of its p65 subunit and the phosphorylation of inhibitor of nuclear factor kappa-B kinase subunits alpha and beta, which are markers of NF-κB pathway activation. Inhibition of the NF-κB pathway in PTOV1 -overexpressing ovarian cancer cells increased CDDP-induced apoptosis, suggesting that PTOV1 promoted chemotherapy resistance by activating the NF-κB pathway. In summary, we identified PTOV1 as a prognostic factor for patients with ovarian cancer. PTOV1 might be a target for inhibition of chemotherapy resistance.

show abstract

Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma

Cited by 8 publications

References 25 publications

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

The role of prostate tumor overexpressed 1 in cancer progression

PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer

Contact Info

Product

Resources

About